Brief: Cinclus Pharma Partners With Zentiva
22/05/2025 06:52
May 22 (Reuters) - Cinclus Pharma Holding publ AB CINPHA.ST: CINCLUS PHARMA PARTNERS WITH ZENTIVA TO COMMERCIALIZE LINAPRAZAN GLURATE IN EUROPE TOTAL DEAL VALUE, INCLUDING UPFRONT AND REGULATORY AND COMMERCIALIZATION MILESTONE PAYMENTS IS EUR 220 MILLION, WHICH INCLUDES AN UPFRONT PAYMENT OF EUR 13 MILLION AND A NEAR-TERM MILESTONE OF EUR 5 MILLION IN 2026 IS ENTITLED TO TIERED DOUBLE-DIGIT ROYALTIES ON NET SALES IN EUROPE, STARTING IN HIGH-TEENS, EXCEEDING 20% AT HIGHEST TIER LEVELS PRODUCT IS NEXT-GENERATION POTASSIUM-COMPETITIVE ACID BLOCKER FOR TREATMENT OF SEVERE EROSIVE GASTROESOPHAGEAL REFLUX DISEASE Source text: ID:nMFN41KTzy Further company coverage: CINPHA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))